Drug intelligence / Profile preview

GSK586529

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK586529 is a small molecule drug developed by GlaxoSmithKline (GSK) as a corticotropin-releasing factor receptor 1 (CRHR1) antagonist. It has been investigated for potential therapeutic effects in anxiety disorders and depressive disorders. Additionally, there is mention of its potential in oncology and immunology, though this is less detailed.

Targets

CRHR1 (Corticotropin-releasing factor receptor 1)

Beyond the preview

Go deeper on GSK586529.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK586529.

Explore the full profile